Zenosense, Inc. (ZENO) – A Healthcare Tech Compa
Post# of 53
Posted On: 04/14/2015 6:53:20 PM
Zenosense, Inc. (ZENO) – A Healthcare Tech Company on a Mission
Valencia, Spain-based Zenosense is embedded in the emerging healthcare technology arena. Since its establishment in 2008, the company has been focused on developing detection devices.
Nowadays, Zenosense is developing functioning, cost-effective medical devices that will identify, very early on, lethal bacteria or cancers in a patient’s expelled breath. The company has its eye on co-developing two key devices with strategic partners; one device is intended to detect lung cancer and the other to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug” in hospitals and clinical settings.
Considering that there is less than a 20% chance that lung cancer cases will be detected in the fairly treatable first stage of the disease, Zenosense has been a company on a mission lately with its laser focus on co-developing its lung cancer detection device with Zenon Biosystem. Zenon is member of The Sgenia Group, and going all out as Zenosense’s contracted development partner.
Zenosense and Zenon revealed last November that they were building a prototype device for testing during a lung cancer detection trial that would ultimately determine if the device should make its market debut. Since then, Zenon has been striving to create the partnerships needed to perform the planned trial. Zenon has also undertaken the task of manufacturing the tangible prototype. To meet the protocol design terms of the lung cancer detection trial, Zenon will produce two pre-market devices of matching design to ensure that the results of the trial can be duplicated.
Zenosense feels that a breath-analyzing lung cancer detector that is proven to meet or surpass the accuracy of low-dose Computed Tomography (CT) scanning will create wide appeal and subsequent demand. They also believe that the successful development of a high-quality, non-invasive, cost-effective early detection screening method will likely offer major improvements in survival rates and decreases in mortality rates.
For more information, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Valencia, Spain-based Zenosense is embedded in the emerging healthcare technology arena. Since its establishment in 2008, the company has been focused on developing detection devices.
Nowadays, Zenosense is developing functioning, cost-effective medical devices that will identify, very early on, lethal bacteria or cancers in a patient’s expelled breath. The company has its eye on co-developing two key devices with strategic partners; one device is intended to detect lung cancer and the other to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug” in hospitals and clinical settings.
Considering that there is less than a 20% chance that lung cancer cases will be detected in the fairly treatable first stage of the disease, Zenosense has been a company on a mission lately with its laser focus on co-developing its lung cancer detection device with Zenon Biosystem. Zenon is member of The Sgenia Group, and going all out as Zenosense’s contracted development partner.
Zenosense and Zenon revealed last November that they were building a prototype device for testing during a lung cancer detection trial that would ultimately determine if the device should make its market debut. Since then, Zenon has been striving to create the partnerships needed to perform the planned trial. Zenon has also undertaken the task of manufacturing the tangible prototype. To meet the protocol design terms of the lung cancer detection trial, Zenon will produce two pre-market devices of matching design to ensure that the results of the trial can be duplicated.
Zenosense feels that a breath-analyzing lung cancer detector that is proven to meet or surpass the accuracy of low-dose Computed Tomography (CT) scanning will create wide appeal and subsequent demand. They also believe that the successful development of a high-quality, non-invasive, cost-effective early detection screening method will likely offer major improvements in survival rates and decreases in mortality rates.
For more information, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)